Intelligence Platform

Patents

Browse 405 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 10485796

LPT-723 and immune checkpoint inhibitor combinations and methods of treatment

Biomed Valley Discoveries, Inc. · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10478430

Compounds useful as inhibitors of ATR kinase and combination therapies thereof

Vertex Pharmaceuticals Incorporated · Granted Tue Nov 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10471142

Combination therapy using immunoglobulin and C1-Inhibitor

THE GOVERNMENT OF THE UNITED STATES OF AMERICA · Granted Tue Nov 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10471144

Combination of local rose bengal and systemic immunomodulative therapies for enhanced trea

Provectus Pharmatech, Inc. · Granted Tue Nov 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10463652

Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions there

VTV THERAPEUTICS LLC · Granted Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10463654

Combination therapies for treating cancer

RedHill Biopharma Ltd. · Granted Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10456390

Combinations comprising MABA compounds and corticosteroids

Almirall, S.A. · Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10451610

Prediction of response to PARP inhibitors and combinational therapy targeting C-MET and PA

The Board of Regents of the University of Texas System · Granted Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10434078

GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA co

The Regents of the University of California · Granted Tue Oct 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10434174

Combination therapies using platinum agents and agents that target tumor-associated stroma

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10426786

Mitigation of epileptic seizures by combination therapy using benzodiazepines and neuroste

The Regents of the University of California · Granted Tue Oct 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10420812

Drug combinations and uses in treating a coughing condition

Infirst Healthcare Limited · Granted Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10406125

Combination comprising an aminothiolester compound or a pharmaceutically acceptable salt t

ADVANCED BIODESIGN · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10376588

Etanercept formulations stabilized with combinations of sugars and polyols

Coherus BioSciences, Inc. · Granted Tue Aug 13 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10369142

Combination dosage form of a mu opioid receptor antagonist and an opioid agent

Theravance Biopharma R&D IP, LLC · Granted Tue Aug 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10357553

Compositions and methods for combination therapy with dengue virus and dendritic cells

PrimeVax Immuno-Oncology · Granted Tue Jul 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10286065

Compositions and methods for treating viral infections through stimulated innate immunity

The Board of Regents of the University of Texas System · Granted Tue May 14 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 09 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10272099

Tumor-selective combination therapy

The Board of Regents of the University of Texas System · Granted Tue Apr 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10238698

Biomarkers and combination therapies using oncolytic virus and immunomodulation

The Board of Regents of the University of Texas System · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10232041

Combination of lenalidomide and polypeptide construct, and uses thereof

TEVA PHARMACEUTICALS PTY LTD · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10221244

Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer

Five Prime Therapeutics, Inc. · Granted Tue Mar 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10213389

Controlled release compositions comprising a combination of isosorbide dinitrate and hydra

RECRO GAINESVILLE LLC · Granted Tue Feb 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10206932

Natural combination hormone replacement formulations and therapies

Compass Therapeutics LLC · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10172840

Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions there

VTV THERAPEUTICS LLC · Granted Tue Jan 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted